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Summary
Background Previous attempts to assess the prevalence of drug use in Afghanistan have focused on subgroups that 
are not generalisable. In the Afghanistan National Urban Drug Use Study, we assessed risk factors and drug use in 
Afghanistan through self-report questionnaires that we validated with laboratory test conﬁ rmation using analysis of 
hair, urine, and saliva.
Methods The study took place  between July 13, 2010, to April 25, 2012, in 11 Afghan provinces . 2187 randomly selected 
households completed a survey, representing 19 025 ho usehold members. We completed surveys with the female 
head of the household about past and current drug use among members of their household . We also obtained hair, 
urine, and saliva samples  from 5236 people in these households and tested them for metabolites of 13 drugs.
Find ings Of 2170 households with biological samples tested, 247 (11·4%) tested positive for any drug. Overall, opioids 
were the most prevale nt drug in the biological samples (5·6%), although prescription drugs (prescription pain pills, 
sedatives, and tranquilliser) were the most commonly reported in the past 30 days in the questionnaires (7·6%). Of 
individuals testing positive for at least one substance, opioids accounted for more than 50% of substance use in 
women and children, but only a third of substances in men, who predominantly tested positive for cannabinoids. 
After controlling for age with direct standardisation,  individual prevalence of substance use (from laboratory tests) 
was 7·2% (95% CI 6·1–8·3) in men and 3·1% (2·5–3·7) in women—with a national prevalence of 5·1% (4·4–5·8) 
and a prevalence of 5·0% (4·1–5·8) in Kabul. Concordance between laboratory test results and self-reports was high.
Interpretation These data suggest the female head of household to be a knowledgeable informant for household 
substance use. They also might provide insight into new avenues for targeted behavioural interventions and 
prevention messages.
Funding US Department of State.
Copyright © Cottler et al. Open Access article distributed under the terms of CC BY-NC-ND.
Introduction
Little research has been done on illicit drug use in 
Afghanistan, even though most of the world’s opium 
originates in the country.1 To develop interventions to 
reduce use, reliable epidemiological studies are needed. 
Knowledge of drug use in Afghanistan comes mainly 
from studies on subgroups such as female sex workers 
or drug users in treatment (from a voluntary counselling 
and testing centre),2–5 and from a study of informants 
who might have known a drug user.6 However, these 
methods introduce information and sampling biases 
that would misrepresent drug use.
To address this serious gap in knowledge, the 
Afghanistan National Urban Drug Use Study 
(ANUDUS) was launched under the direction of the 
University of Florida (UF) in July 13, 2010. With 
multistage sampling, ANUDUS randomly selected 
households from 11 provincial capitals to assess 
substance use in household members (through hair, 
saliva, and urine samples) and through questions to 
female heads of the household. We present the 
prevalence of household and individual substance use 
from both self-report and biological tests. We postulated 
that refusal rates would be low, that people would 
provide biological samples for testing, that women 
would be good reporters of the household behaviours, 
that prevalence of substance use would be higher for 
men than for women, that pharmaceutical drug use 
would be high, and that opioids would be the most 
commonly used substances.
Methods
Sampling
The survey was done in the capitals of 11 Afghan 
provinces with the least safety issues for the study teams. 
We purposively selected regions contiguous with Iran 
and central Asia where access to drugs was thought to be 
high (Kabul, Nangarhar, Balkh, and Hirat; ﬁ gure 1). 
Additionally, mountainous terrain, severe weather, and 
war excluded some areas from the study. We stratiﬁ ed 
provinces into ﬁ ve regions: northeast (Badakhshan); east 
(Nangarhar); north (Faryab, Jawzjan, Balkh, and 
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Bamyan), west (Hirat, Farah, and Nimroz); and central 
(Parwan). Kabul was included as a central region but was 
separated because of its large population.
We began phase one multistage sampling (July 13, 2010, 
to July 8, 2011) by selecting each province’s capital city 
(ﬁ gure 1). We enumerated police districts, used as the 
anchor point for sampling, and then selected them 
randomly. We then selected a random interval to choose 
households in each district. To maintain conﬁ dentiality, 
we do not report the start point and interval between 
houses. The overall phase one sample of 1007 households 
represented at least 0·25% of the population in each 
provincial capital.
Initially, we included three of 16 police districts for 
Kabul, limiting the statistical use of the sampling of 
this populous city. Thus, we started phase two (Nov 2, 
2011, to April 25, 2012) in the remaining 13 police 
districts of Kabul. Based on a Kabul population of 
3 289 000 people with a mean of 8·7 people living 
together (378 046 households), the 1180 households 
selected represented 0·31% of Kabul households.
Consent procedures were approved by the Afghanistan 
Ministry of Health and the Washington University 
School of Medicine Institutional Review Board, and 
protocols and assessments were approved by the 
Chesapeake Private Institutional Review Board 
(Columbia, MD, USA).
Field team and survey administration
The ﬁ eld staﬀ  (teams of two women and one man) 
included Afghan physicians, anthropologists, and support 
personnel. Field team members were trained in Dubai 
(United Arab Emirates) on proper ﬁ eld procedures, 
administration of the assessment and biological sampling, 
household enumeration techniques, and local and cultural 
aspects of recruitment and engagement. The male team 
member introduced the study to the neighbourhood elder 
and then began the household selection process. Once the 
household was designated, the male team member 
described the study to the male head of each household, 
obtained informed consent of the household in a culturally 
appropriate manner, and enumerated the household by 
age and sex with use of our enumeration matrix. Adults 
were deﬁ ned as individuals aged 15 years or older. The 
female head of the household (deﬁ ned as the woman who 
knew the most about the members of the household) was 
then approached separately for participation. We selected 
female heads of household because they are good 
reporters of family risk factors and outcomes.7 Consenting 
women were surveyed by the two female team members, 
one who asked questions in Dari (the lingua franca 
[bridge] language in Kabul and in Afghanistan generally),8 
and the other who documented answers on the English 
language survey. Conﬁ dentiality was assured by moving to 
a secured, secluded area of the house. The ANUDUS 
Figure 1: Map of provinces surveyed in the Afghanistan National Urban Drug Use Study (ANUDUS), 2012
HH=households.
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survey, developed by the UF and Afghanistan study team, 
included an enumeration matrix of the household, and 
questions about the home, neighbourhood characteristics, 
and patterns of drug and alcohol use for all members of 
the household, including children. The female head of 
household was queried about lifetime and past 30 day use 
of opium, heroin, cannabis or charas, prescription drugs 
(prescription pain pills, sedatives, and tranquillisers), 
alcohol, and tobacco; the reasons for use; and routes taken 
for any drugs, for men, women, and children in the 
household. We analysed data separately by sex and for 
adults only. Women who responded more than 0 to the 
question: “in the past 30 days, how many (PEOPLE) used 
opium?” were asked “which (PEOPLE) used opium?”, and 
we coded the user according to the enumeration matrix. 
For heroin and cannabinoids, we assumed that if a woman 
reported use of heroin or cannabinoids for a male 
household member, then it was for the tested adult man. 
Codes linked to the enumeration matrix allowed the team 
to determine concordance between self-report and 
biological specimen data.
After internal pretesting, an Afghan scholar reviewed 
the assessment, which was then sent to the Afghanistan 
ﬁ eld team for cultural acceptability, feasibility testing, and 
Dari translation. A 2 week testing phase was done at the 
beginning of the study, and no data from the testing were 
used in this study. The team then did a vigorous review of 
the assessment to ensure the proper skip patterns (a 
series of questions associated with a conditional 
response). Protocol manuals were developed for quality 
control and ﬁ delity checks throughout the study. Mostly, 
the testing helped add information to the protocol manual 
such as the best time of day to visit households and that 
female survey administrators should go in pairs. We also 
changed cannabis to charas and added new names for 
routes of drug use.
Laboratory sample collection and testing
In addition to survey data, the teams obtained hair, saliva, 
and urine samples from the female head of household 
(primary respondent), the oldest man, and the youngest 
child aged 4–14 years (if applicable). For children, parents 
took the child to the private bathroom and obtained urine 
while the child urinated. Samples from other household 
members were collected while the female head of the 
household was being interviewed. After the interview, the 
teams obtained hair, saliva, and urine samples from the 
female head of the household.
The teams sent the samples of hair, saliva, and urine to 
Des Plaines, IL, USA, for testing at the US Drug Testing 
Laboratories (USDTL). Survey data and specimens were 
always shipped separately to maintain the integrity and 
conﬁ dentiality of the data.
Hair samples were tested with use of the HairStat-10 
test (USDTL, Des Plaines, IL, USA), with 1000 pg/mg 
screen limits for barbiturates, benzodiazepines, 
propoxyphene, and methadone; 500 pg/mg screen 
limits for amphetamines and cocaine; 300 pg/mg 
screen limit for phencyclidine (PCP); 200 pg/mg screen 
limits for opiates and oxycodone; and a 5 pg/mg screen 
limit for cannabinoids. The presence of 
6-acetylmorphine was used for heroin use in hair, 
saliva, and urine. Saliva samples were tested using the 
OralStat-10 test (USDTL), with screen limits of 
50 ng/mL for amphetamines, barbiturates, and 
methadone; 40 ng/mL for opiates, oxycodone, and 
propoxyphene; 20 ng/mL for benzodiazepines and 
cocaine; 10 ng/mL for PCP; and 4 ng/mL for 
cannabinoids. A 10-panel urine proﬁ le was done for 
urine samples, with a 1000 ng/mL screen limit for 
amphetamines; 500 ng/mL for ecstasy 
(MDMA); 300 ng/mL for cocaine, methadone, opiates, 
propoxyphene, and oxycodone; 200 ng/mL for 
barbiturates and benzodiazepines; 25 ng/mL for PCP; 
20 ng/mL for cannabinoids and ethanol; and 10 ng/mL 
for 6-acetylmorphine. All positive tests were successfully 
conﬁ rmed by gas chromatography mass spectrometry 
(GC-MS) or liquid chromatography tandem mass 
spectrometry (LC-MS/MS).
We formulated several broad categories for drug use 
based on positivity for metabolites. Amphetamine-
positive meant testing positive for amphetamine or 
methamphetamine. Barbiturate-positive was attributed 
to phenobarbital. Benzodiazepine use was attributed to 
diazepam, nordiazepam, oxazepam, temazepam, or 
zehydroxyalprazolam. Cannabinoid positivity was 
indicated by native tetrahydrocannabinol (THC—oral) or 
carboxy-THC (THCA—urine). We considered anyone 
testing positive for codeine, morphine, or 
6-acetylmorphine in saliva or urine to have tested positive 
for opium or heroin. To conﬁ rm that ethanol was due to 
the ingestion of alcohol, rather than fermentation, we 
ran tests for ethyl glucuronide (EtG) and ethyl sulfate 
(EtS). Only tests that were positive for EtG were classiﬁ ed 
as alcohol positive. 
Statistical analysis
Quality control measures were implemented from the 
point of the initial testing through the end of the ﬁ eld 
period. Each survey was reviewed for accuracy, skip-pattern 
errors, and potential inconsistencies in responses. 
Deidentiﬁ ed samples were reviewed for security in 
transport and proper coding. Fidelity to the protocols was 
monitored during weekly conference calls with the Afghan 
and Cottler teams.
Drug use was categorised by household and individual, 
and stratiﬁ ed by province, age and sex. To assess 
agreement (concordance) between self-reported recent 
drug use and positive laboratory tests, we report both the 
Cohen κ statistic and Yulee Y test. 9,10 A measure of 1 
indicates high agreement that is not due to chance, 
whereas a measure of zero indicates chance agreement. A 
measure of –1 indicates high disagreement that is not due 
to chance.11
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We used the results of the laboratory tests to calculate 
national prevalence. Because we tested more than one 
person per household, the individual prevalence is not 
equivalent to the true population prevalence of 
substance use in Afghanistan. To obtain such an 
estimate, we controlled for age through direct age 
standardisation and then used proc surveyselect in SAS 
9.3 to randomly select one person tested per household. 
On the basis of this selection, overall national and 
Kabul prevalence rates were estimated to reduce the 
eﬀ ect of clustering within households. To ensure this 
rate was not subject to chance, we did 100 simulations 
and took an average.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. LBC had full access to all the data in the study 
and maintains the database now. All authors had ﬁ nal 
responsibility for the decision to submit for publication. 
Northeast East North West Central Total (n=2187)
Badakhshan (n=99) Nangarhar (n=98) Balkh, Bamyan, Faryab, 
and Jawzjan (n=298)
Hirat, Farah, and 
Nimroz (n=249)
Parwan 
(n=100)
Kabul 
(n=1343)
Age and sex
Age of household members (years) 23·0 (6·4) 19·7 (4·8) 23·0 (6.8) 21·7 (7·2) 22·9 (7·4) 23·3 (7·7) 22·9 (7·4)
Number of people in surveyed household 8·3 (2·8) 10·7 (4·0) 8·2 (3·0) 7·8 (2·9) 8·2 (3·2) 8·9 (3·8) 8·7 (3·6)
Men and boys in household 4·5 (2·1) 5·5 (2·6) 4·1 (1·9) 4·0 (1·9) 4·1 (2·1) 4·5 (2·2) 4·4 (2·2)
Women and girls in household 3·9 (1·6) 5·3 (2·2) 4·2 (1·9) 3·9 (1·8) 4·1 (1·9) 4·4 (2·3) 4·3 (2·2)
Ethnic origin
Tajik 91 (92%) 19 (19%) 112 (38%) 114 (46%) 99 (99%) 790 (59%) 1225 (56%)
Pashtum 1 (1%) 74 (76%) 25 (8%) 121 (49%) 1 (1%) 301 (22%) 523 (24%)
Uzbek 3 (3%) 0 106 (36%) 1 (<1%) 0 16 (1%) 126 (6%)
Hazara 0 0 45 (15%) 6 (2%) 0 225 (17%) 276 (13%)
Turkmen and other ethnic origins 4 (4%) 5 (5%) 10 (3%) 7 (3%) 0 11 (1%) 37 (2%)
International domicile
One household member who lived in another 
country in past 5 years
8 (8·1%) 10 (10%) 46 (15%) 65 (26%) 13 (13%) 227 (17%) 369 (17%)
Mean (SD) given for continuous variables; numbers (%) given for categorical variables.
Table 1: Demographic characteristics of surveyed Afghan households by region
Northeast East North West Central Total (n=2170)
Badakhshan (n=99) Nangarhar (n=97) Balkh, Bamyan, 
Faryab, Jawzjan 
(n=295)
Hirat, Farah, Nimroz 
(n=249)
Parwan (n=97) Kabul (n=1333)
Amphetamines 0 0 0 2 (0·8% [0·0–1·9]) 0 0 2 (0·1% [0–0·2])
Barbiturates 0 2 (2·1% [0·0–4·9]) 1 (0·3% [0·0–1·0]) 1 (0·4% [0·0–1·2]) 0 9 (0·7% [0·2–1·1]) 13 (0·6% [0·3–0·9])
Benzodiazepines 0 3 (3·1% [0·0–6·5]) 6 (2·0% [0·4–3·6]) 10 (4·0% [1·6–6·5]) 4 (4·1% [0·2–8·1]) 32 (2·4% [1·6–3·2]) 55 (2·5% [1·9–3·2])
Any amphetamine, 
barbiturates, and 
benzodiazepines
0 5 (5·2% [0·8–9·6]) 7 (2·4% [0·6–4·1]) 12 (4·8% [2·2–7·5]) 4 (4·1% [0·2–8·1]) 40 (3·0 % [2·1–3·9]) 68 (3·1% [2·4–3·9])
Cannabinoids 0 3 (3·1% [0·0–6·5]) 5 (1·7% [0·2–3·2]) 7 (2·8% [0·8–4·9]) 3 (3·1% [0·0–6·5]) 52 (3·9% [2·9–4·9]) 70 (3·2% [2·5–4·0])
Ethanol 0 0 0 3 (1·2% [0·0–3·2]) 1 (1·1% [0–3·2]) 10 (0·8% [0·3–1·2]) 14 (0·7% [0·3–1·0])
Any opioid 7 (7·1% [2·0–12·1]) 2 (2·1% [0·0–4·9]) 11 (3·7% [1·6–5·9]) 33 (13·3% [9·0–17·5]) 3 (3·1% [0–6·5]) 66 (5·0% [3·8–6·1]) 122 (5·6% [4·7–6·6])
Predominantly 
heroin*
3 (3·0% [0·0–6·4]) 0 1 (0·3% [0–1·0]) 8 (3·2% [1·0–5·4]) 0 13 (1·0% [0·4–1·5]) 25 (1·2% [0·7–1·6])
Predominantly 
opium*
5 (5·1% [0·8–9·5]) 1 (1·0% [0–2·3]) 9 (3·0% [1·0–5·0]) 13 (5·2% [2·5–7·9]) 2 (2·1% [0·1–4·1]) 25 (1·9% [1·1–2·6]) 55 (2·5% [1·9–3·2])
Predominantly 
codeine*
0 1 (1·0% [0–2·3]) 1 (0·3% [0–1·0]) 14 (5·6% [2·8–8·4]) 1 (1·1% [0–3·2]) 26 (2·0% [1·2–2·7]) 43 (2·0% [1·4–2·6])
Prescription opioid* 0 0 0 0 0 5 (0·4% [0–0·7]) 5 (0·2% [0–0·4])
Any positive test  7 [7·1% [2·0–12·1]) 10 (10·3% [4·3–16·4]) 21 (7·1% [4·2–10·1]) 52 (20·9% [15·8–25·9]) 9 (9·3% [3·5–15·1]) 148 (11·1% [9·4–12·8]) 247 (11·4% [10·0–12·7])
Data are n (% [95% CI]). Numbers are any households where one individual tested positive for substances in hair, urine, or saliva. *Categories not mutually exclusive for single household.
 Table 2: Households that tested positive for substances by region
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Results
Of the 2683 households approached, 2187 (82%) 
completed the survey, representing 19 025 people. 
Reasons for not completing the survey were no 
individuals at home (135 households, 5% of households 
approached), no woman available for interview (104, 4%), 
survey break-oﬀ  (ie, started the survey but failed to 
complete it; 4, 0·1%), and no woman living at home (3, 
0·1%). Among households surveyed, 2170 provided at 
least one sample. 5236 people were tested. When missing 
data were accounted for, the sample totalled 2155 female 
heads of household (99%), 1370 adult men (63% of the 
2170 households with men), and 1705 children (86% of 
the 1985 households with children). The lower test rate 
for men was attributable mainly to their schedules and 
bald heads; only ﬁ ve men declined despite being available 
and having hair (the reason for refusal was not asked). 
After repeated attempts to include the oldest man, we 
sampled the next oldest man, resulting in 20% of men 
being recruited in this way.
The mean age of the 19 025 people sampled was 
22·9 years (table 1). The mean age of female respondents 
tested was 42·1 years (SD 13·3) and the mean age of 
male respondents was 44·7 years (19·4); the mean age of 
the children tested was 6·4 years (2·4). About nine people 
were living in the households, with male and female 
individuals equally distributed. Ethnic origin varied by 
region and province, with most households reporting 
Tajik ethnicity, followed by Pashtun (table 1). More than a 
sixth of the women reported that someone in their 
household had lived outside Afghanistan in the past 
5 years (table 1). 
Of 2170 households, 247 (11%) had at least one person 
who tested positive for at least one substance (table 2). 
Opioids were the most common ﬁ nding in hair, urine, 
or saliva at the household level, with a prevalence of 
5·6%. The west region had the highest household 
prevalence of opioids, whereas the lowest prevalence 
was in the east region (table 2). Seven households in 
Badakhshan had someone who tested positive for 
opioids, but no one tested positive for any other drugs 
(table 2). In a sensitivity analysis on individuals testing 
positive for opioids living or working outside Afghanistan 
in the past 5 years, no diﬀ erences were found between 
those who lived or worked outside Afghanistan and 
those who did not. Income also did not diﬀ erentiate 
opium or heroin users.
Cannabinoids were the next most commonly found 
substance in samples (70 households [3·2%]; table 2). 
Cannabinoid-positive tests were most frequent in Hirat 
and Kabul. Benzodiazepines were the third most 
frequently found substances (55 households [2·5%]). 
When amphetamines, barbiturates, and benzodiazepines 
were combined, the household prevalence was nearly the 
same as for cannabinoids (68 [3·1%]). Of note was the low 
prevalence for ethanol use (14 [0·7%]). No positive results 
occurred for PCP, MDMA, and cocaine.
In all provinces, more men (147; 10·7%) tested positive 
for substances than did women (92; 4·3%) and children 
(39; 2·2%; ﬁ gure 2). Prevalence ranged from a low of 4% 
in Bamyan to a high of 28% in Nimroz, with prevalence 
highest in the west region. Except for in Badakhshan, 
more women tested positive for substances than did 
children (from 0% in Bamyan to 14% in Nimroz). 
Prevalence in children ranged from 0% in several 
provinces to 6% in Farah. Prevalence for women and 
children was also highest in the west.
In Kabul, 90 men (9·9%), 49 women (3·7%), and 
22 children (2·6%) tested positive for a substance. When 
we stratiﬁ ed data for the Kabul province by geographical 
quadrants (northeast, northwest, southwest, and 
southeast), no signiﬁ cant diﬀ erences were shown in 
demographic characteristics except for ethnic origins; 
people in the southwest were predominantly Hazara 
rather than Tajik. Of the 1343 households within Kabul, 
148 households (11·1%) tested positive for at least one 
Figure 2: Individual prevalence of positive tests for substance use by region, province, sex, and age
Data based on positive results in hair, saliva, or urine tests. Categories are mutually exclusive.
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substance. The drug most commonly shown by 
laboratory tests was opioids (66; 4·9%); whereas the most 
commonly self-reported substances were prescription 
drugs (126; 9·4%). When stratiﬁ ed by sex and age, men 
in the east of Kabul had the highest prevalence of 
substance use (12·3%) compared with other regions, 
whereas women (9·2%) and children (3·7%) from the 
west had the highest use.
After direct age standardisation, we estimate the 
national prevalence of substance use in Afghanistan to 
be 7·2% (95% CI 6·1–8·3) for men and 3·1% (2·5–3·7) 
for women. When adjusted for clustering within 
households, we estimate the national prevalence of drug 
use in Afghanistan to be 5·1% (4·4–5·8), and 5·0% 
(4·1–5·8) in Kabul.
Figure 3 shows the pattern of substance use in men, 
women, and children who tested positive for any 
substance. Those testing positive for more than one 
substance were considered polysubstance users. In the 
278 individuals who tested positive, opioids accounted 
for just more than 60% of positive tests for substances in 
women and children, followed by cannabinoids in 
children (24%), and benzodiazepines among women 
(31%). In men, the most commonly found substance was 
cannabinoids (36%), followed by opioids (34%). Positive 
tests for cannabinoids were rare in women (1%). 
Amphetamines were found only in men. Men were ﬁ ve 
times more likely than were women and children to test 
positive for more than one substance (ﬁ gure 3). 
Polysubstance use was largely attributed to opioids and 
benzodiazepines (46%), and to opioids and cannabinoids 
(33%). In the rest of polydrug users, opioids were found 
in all but one person.
We analysed self-reported household drug use and 
related behaviours (reported by female head of the 
household on behalf of all members) by region (table 3) 
and sex (appendix). The lifetime self-reported household 
prevalence of opium or heroin use for any reason was 4·5% 
for men and 3·3% for women (appendix). The past 30 day 
self-reported prevalence of opium or heroin use in men 
was ﬁ ve times that of women (1·5% vs 0·3%), and a third of 
the rate of lifetime prevalence, with percentages highest in 
the west regions (appendix). All women who reported past 
30 day use of a substance in any family member within 
their household also consistently reported lifetime use for 
that same substance for themselves (data not shown). For 
cannabinoid (charas) use, the self-reported lifetime 
prevalence was 7·1%; nearly all use was in men, with a 
prevalence higher than for opium or heroin (appendix). 
Although more than half of the lifetime charas use was 
reported to be current (3·9%), no women were reported to 
be current users of charas. Prescription pain pills, sedatives, 
and tranquillisers were reportedly used by 18·4% of people 
in their lifetime and were the most commonly reported 
Figure 3: Patterns of positive tests by sex and age group
Data based on positive results in hair, saliva, or urine tests. Categories are 
mutually exclusive.
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Northeast East North West Central Total (n=2187)
Badakhshan (n=99) Nangarhar (n=98) Balkh, Bamyan, 
Faryab, and Jawzjan 
(n=298)
Hirat, Farah, and 
Nimroz (n=249)
Parwan (n=100) Kabul (n=1343)
Any self-reported lifetime use of 
heroin or opium
5
(5·1% [0·7–9·4])
3
(3·1% [0·0–9·4])
19
(6·4% [3·6–9·2])
22
(8·8 [5·3–12·4])
3
(3·0% [0–6·3])
97
(7·2% [5·8–8·6])
149
(6·8% [5·8–7·9])
Any self-reported past 30 day use 
of heroin or opium
1
(1·0% [0–3·0])
0 7
(2·3% [0·6–4·1])
8
(3·2% [1·0–5·4])
2
(2·0% [0–4·7])
20
(1·5% [0·8–2·1])
38
(1·7% [1·2–2·3])
Any self-reported liftetime use of 
charas
8
(8·1% [2·7–13·5])
12
(12·2% [5·7–18·7])
20
(6·7% [3·9–9·6])
7
(2·8% [0·8–9·6])
9
(9·0% [3·4–14·6])
99
(7·4% [6·0–8·8])
155
(7·1% [6·0–8·2])
Any self-reported past 30 day use 
of charas
0 0 0 0 0 0 0
Any self-reported lifetime use of 
pills*
6
(6·1% [1·4–10·8])
10
(10·2 [4·2–16·2])
20
(6·7 [3·9–9·6])
32
(12·9% [8·7–17·0])
7
(7·0% [2·0–12·0])
328
(24·4% [22·1–26·7])
403
(18·4% [16·8–20·1])
Any self-reported past 30 day use 
of pills*
5
(5·1% [0·7–9·4])
3
(3·1% [0·0–6·5])
11
(3·7% [1·5–5·8])
18
(7·2% [4·0–10·4])
3
(3·0% [0–6·3])
126
(9·4% [7·8–10·9])
166
(7·6% [6·5–8·7])
Data are n (% [95% CI]). *Includes prescription pain pills, sedatives, and tranquillisers.
 Table 3: Household drug use reported by the female head of the household by region
See Online for appendix
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drugs in women, with a prevalence nearly triple that of 
men (14·5% vs 5·3%; appendix). Reported alcohol use was 
low in men (data not shown); no alcohol use was reported 
for either women or children. Cigarette (chillum) use was 
the most commonly reported substance for adults (28·6%), 
but was rare in children (0·1%).
Overall 166 (7·6%) women reported that a neighbour 
used opium (table 4), but reports that people in their 
neighbourhood cultivated poppy or were thrown out of 
the household due to substance use were rare. 41% of the 
women surveyed believed that more women were now 
using opium or heroin compared with 5 years ago. This 
number was similar for cannabis; pills, sedatives, or 
tranquillisers; and alcohol (table 4). Perceptions about 
trends in use mimicked their reports about their 
neighbours’ use.
We also collected self-reported lifetime use of mufara 
(a preparation made from opium, hashish and sugar 
and eaten like chocolate), petrol, shoe polish, acetone, 
datura (also known as dantoorah or gul-e-khapiray, 
which grows wild all over Afghanistan), ketamine, 
cough syrup, and glue. Use of all substances apart from 
petrol inhalation was negligible or non-existent, except 
for in Kabul where 60, 34, and 7 households reported 
lifetime use of inhaled petrol (4·5%), acetone (2·5%), 
and shoe polish (0·5%), respectively.
Agreement was high between test results and self-
reports for opium or heroin in men and women and for 
household charas use (96–99%; table 5). There was 
moderate to excellent agreement between the woman’s 
report of current heroin or opium use and the man’s 
laboratory result (Yule’s Y 0·78), excellent agreement 
between a woman’s self-report and her own laboratory 
results (0·88), and moderate agreement for household 
cannabinoid use (0·68; table 5).
Discussion
ANUDUS is the ﬁ rst epidemiological study of households 
in Afghanistan to assess both self-report and laboratory-
based testing for drugs and alcohol, and is now the most 
comprehensive assessment of substance use and its 
correlates in Afghanistan (panel). Our high response rate 
(81·5%) is higher than many epidemiological studies 
around the world12—attributed to the welcoming 
recruitment style of our interview team—adding to our 
conﬁ dence in the results.
Overall substance use in individuals (a positive 
laboratory test) was high, with a prevalence of 11% in 
men, 4% in women, and 2% in children. Opioids were 
the most common positive results. Opium use was most 
often found in the northeast and west regions, which 
could be due to higher access of the drugs. In all 
provinces, laboratory tests showed cannabinoids to be 
only the second most prevalent drugs. Contrary to 
expectations, we did not ﬁ nd a high prevalence of 
prescription opioids in any region. The low prevalence of 
polysubstance use among women (4%) and children 
(3%), compared with that of men (13%) was noteworthy 
(ﬁ gure 3), indicating a need for more research in 
these areas.
Northeast East North West Central Total
Badakhshan (n=99) Nangarhar (n=98) Balkh, Bamyan, 
Faryab, Jawzjan 
(n=298)
Hirat, Farah, Nimroz 
(n=249)
Parwan (n=100) Kabul (n=1343) (n=2187)
At present, is there
Anyone in neighbourhood 
who uses opium?
9
(10·5% [4·0–16·9])
7
(9·2% [2·7–15·7])
19
(9·0% [5·2–12·9])
24
(16·8% [10·7–22·9])
10
(13·0% [5·5–20·5])
97
(12·7% [10·4–15·1])
166
(7·6% [6·5–8·7])
Anyone in neighbourhood 
who trades opium for 
goods or services?
4
(4·0% [0·2–8·2])
2
(2·7% [0·0–6·4])
3
(1·4% [0·0–3·0])
11
(7·2% [3·1–11·3])
1
(1·0% [0–3·0])
33
(4·5% [3·0–6·0])
54
(2·5% [1·8–3·1])
Anyone in neighbourhood 
who cultivates poppy?
4
(4·0% [0·2–8·2])
0 1
(0·3% [0·0–1·0])
0 1
(1·0% [0–3·0])
0 6
(0·3% [0·1–0·5])
Anyone who has been 
thrown out because of 
drug or alcohol use?
1
(1·0% [0·0–3·0])
1
(1·0% [0·0–3·0])
2
(0·7% [0·0–1·6])
3
(1·2% [0·0–2·6])
1
(1·0% [0–3·0])
11
(0·8% [0·3–1·3])
19
(0·9% [0·5–1·3])
Compared to 5 years ago, do you think that more women are using
Opium or heroin? 19
(19·2% [11·4–27·0])
18
(18·4% [10·7–26·0])
101
(33·9% [28·5–39·3])
131
(52·6% [46·4–58·8])
35
(35% [25·6–44·4])
597
(44·5% [41·8–47·1])
901
(41·2% [39·1–43·3])
Cannabis? 17
(17·2% [9·7–24·6])
19
(19·4% [11·6–27·2])
74
(24·8% [19·9–29·7])
107
(43·0% [36·8–49·1])
28
(28·0% [19·2–36·8])
512
(38·1% [35·5–40·7])
757
(34·6% [32·6–36·6])
Pain pills, sedatives, or 
tranquillisers?
13
(13·1% [6·5–19·8])
21
(21·4% [13·3–29·6])
63
(21·1% [16·5–25·8])
93
(37·3% [31·3–43·4])
25
(25·0% [16·5–33·5])
535
(39·8% [37·2–42·5])
750
(34·3% [32·3–36·3])
Alcohol? 10
(10·1% [4·2–16·0])
13
(13·3% [6·5–20·0])
61
(20·5% [15·9–25·1])
80
(32·1% [26·3–37·9])
33
(33·0% [23·8–42·2])
444
(33·1% [30·5–35·6])
641
(29·3% [27·4–31·2])
Data are number of positive answers (% [95% CI]). 
Table 4: Perception of drug use and societal issues by female head of the household
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A strength of our study was our pairing of the biological 
samples with self-reports. Whereas average agreement 
with κ was shown for women and moderate agreement 
was shown for men, the more sensitive Yule’s Y (which 
takes into consideration the base rate) showed excellent 
concordance between a woman’s report of her own opium 
or heroin use, moderately high concordance for men’s use, 
and moderate concordance for household cannabinoid 
use. Disagreement between reports and laboratory testing 
might have been due to several reasons: environmental 
exposure via another household member or a visitor to the 
household that the female head of household was unaware 
of; drug use by an individual who was not tested (37% of 
men selected were not home, were bald, or had refused 
testing); positive results caused by use of cough syrup or 
analgesics with opiates in them; or women’s disinclination 
to reveal the truth. Drug concentrations nearly always 
suggested use by the individual rather than secondary 
exposure, but more laboratory tests might have been 
positive had more men been tested. After the ﬁ rst and 
second batch of test results, we put in place additional 
protocols to increase male participation. To avoid confusion 
with prescription medication, a separate question for pain 
pills, sedatives, and tranquilliser might have avoided any 
misclassiﬁ cation bias. However, our ﬁ ndings were 
consistent with global use patterns for higher prevalence 
of prescription pills for women than for men, adding 
conﬁ dence in our data. Additionally, the fact that the 
prevalence of ethanol via self-report agrees with the 
specimen testing is reassuring since drinking alcohol is 
taboo in Afghanistan. Concordance indicates that Afghans 
will divulge sensitive information when the justiﬁ cation 
for information is clearly stated and when the caring and 
professional team provide anonymity and privacy.
More women felt that people in their communities 
were using opium (8%) than our ﬁ ndings showed (6%). 
Moreover, 41% indicated that more women were using 
opium compared with 5 years ago. Although 30% said 
that there was an increase in women’s use of alcohol 
recently, use determined by testing was low (0·07%) and 
attributed to men. This ﬁ nding, and the better than 
average agreement between self-report and laboratory 
samples, reassured us that reports were accurate. Women 
were also consistent in distinctly answering questions 
about use. There were no logical instances where women 
would report 30 day use, but not lifetime use, and there 
was a strong association between use of substances and 
risk factors, such as neighbourhood use.
There were some limitations in our study. First, 
although we tried to survey the household members with 
the most knowledge of the household, these women still 
might not have known the exposure history of all other 
household members. Second, in cities such as Kabul and 
Hirat where homelessness is high,13 the study design did 
not capture the homeless population, thus potentially 
leading to a bias in the estimate of the prevalence. Third, 
we did not ascertain the reliability of the questionnaire by 
resampling a fraction of the households, although 
questions were based on assessments that have been used 
in test-retest studies previously.14–16 The high concordance 
between self-reported and laboratory-tested results 
suggests a good validity of the self-reported questionnaire. 
Fourth, although this is the most comprehensive survey of 
drug and alcohol use in Afghanistan, the national 
prevalence was estimated on the basis on data collected 
from urban areas of 11 provinces. Prevalence of 
pharmaceutical opioid and heroin use could be higher in 
urban areas, whereas more traditional forms of illicit drug 
Survey 
negative 
report
Survey 
positive 
report
Concordance* κ (95% CI) Yule’s Y (95% CI)
Opioid or heroin use in men in household
Negative drug test 1320 12 97·4% 0·42 (0·27–0·58) 0·78 (0·69–0·86)
Positive drug test 24 14 ·· ·· ··
Opioid or heroin use in female HoH
Negative drug test 2143 2 99·5% 0·28 (–0·03 to 0·59) 0·88 (0·77–1·0)
Positive drug test 8 2 ·· ·· ··
Cannabinoid use by any individual in household
Negative drug test 2064 38 96·3% 0·33 (0·22–0·44) 0·68 (0·60–0·76)
Positive drug test 41 21 ·· ·· ··
HoH=head of the household. *Percentage of individuals with results of tests that agreed with report.
Table 5: Concordance between tests (urine or saliva) and reports (self or from female HoH) of drug use in 
past 30 days
Panel: Research in context
Systematic review
Before we launched the study, we searched PubMed for English 
articles with no date restrictions with combinations of search 
terms including “substance use”, “drug use”, “amphetamines”, 
“barbiturates”, “benzodiazepines, “alcohol use”, “opioid”, 
“heroin”, “opium”, “codeine”, “injection drug user”, “mufara”, 
“petrol”, “shoe polish”, “acetone”, “datura”, “ketamine”, “cough 
syrup”, “glue”, and “Afghanistan”. The search was last updated 
on May 31, 2014. Few studies have used credible methods.2–6 
Almost all of the previous studies were done with key 
informants and subgroups such as female sex workers or drug 
users receiving treatment, which introduced information and 
sampling biases that reduced generalisability. 
Interpretation
In urban regions of Afghanistan, after age standardisation, 7% 
of men and 3% of women tested positive for drugs. The 
national prevalence of substance use was 5%. Our results 
show that the female head of the household was a 
knowledgeable informant about household substance use. 
There is some evidence for an increase in psychoactive drug 
use in Afghanistan and that children are increasing being 
exposed to opioids. These ﬁ ndings provide insight to help 
inform possible individual and community substance use 
intervention and prevention measures.
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use such as opiate smoking and cannabis might be more 
common in more remote rural areas. Other limitations 
included our inability to ﬁ nd all selected men at home for 
sample collection. In future work, additional techniques 
should be explored to secure all selected participants.
More analyses are needed for the risk factors associated 
with both self-reported and tested prevalence of substance 
use from households and individuals. The use of petrol 
and acetone warrants further interventions.
In conclusion, we were humbled that household 
members allowed us into their homes; many were actually 
eager to participate in this survey. Although men were not 
as available as we expected them to be for testing, women 
rarely refused the survey or testing and were good to 
excellent reporters about their household. Our results 
suggest that drug use in Afghanistan is prevalent, higher 
in men than in women, and that the substance most 
commonly found in hair, urine, or saliva was opioids. 
Opioids were the most common positive result in women 
and children; however, the most commonly reported 
drugs by women were prescription drugs, with past 30 day 
prevalence for women twice that for men. This alarming 
prevalence deserves our continued attention.17
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